An Evaluation of LY007 Cell Injection for r/r B-NHL

This trial is testing a CAR-T cell therapy called LY007 for people with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) — a blood cancer that has come back or stopped responding to treatment. CAR-T therapy involves modifying your own immune cells in a lab and reinfusing them to fight the cancer. **You may be eligible if...** - You are between 18 and 70 years old - You have a confirmed diagnosis of CD20-positive B-cell non-Hodgkin lymphoma (including diffuse large B-cell lymphoma or transformed follicular lymphoma) - Your cancer has relapsed or not responded to at least two prior treatments including an anthracycline drug and rituximab (or another CD20-targeting drug) - You are not a candidate for stem cell transplant, or your cancer came back after one - You are in good physical condition (ECOG 0-1) with at least 3 months expected survival - Your heart, lungs, kidneys, and liver are functioning adequately **You may NOT be eligible if...** - You have another active cancer (some exceptions apply) - You have active or poorly controlled infections (including HIV, hepatitis B or C) - You have significant heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.